1. Retinal damage promotes mitochondrial transfer in the visual system of a mouse model of Leber hereditary optic neuropathy
- Author
-
Pascal Ezan, Eléonore Hardy, Alexis Bemelmans, Magali Taiel, Elena Dossi, and Nathalie Rouach
- Subjects
Mitochondrial transfer ,Leber hereditary optic neuropathy ,Retina ,Optic nerve ,Gene therapy ,Viral vector ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Lenadogene nolparvovec is a gene therapy which has been developed to treat Leber hereditary optic neuropathy (LHON) caused by a point mutation in the mitochondrial NADH dehydrogenase 4 (ND4) gene. Clinical trials have demonstrated a significant improvement of visual acuity up to 5 years after treatment by lenadogene nolparvovec but, surprisingly, unilateral treatment resulted in bilateral improvement of vision. This contralateral effect – similarly observed with other gene therapy products in development for MT-ND4-LHON – is supported by the migration of viral vector genomes and their transcripts to the contralateral eye, as reported in animals, and post-mortem samples from two patients. In this study, we used an AAV2 encoding fluorescent proteins targeting mitochondria to investigate whether these organelles themselves could transfer from the treated eye to the fellow one. We found that mitochondria travel along the visual system (optic chiasm and primary visual cortex) and reach the contralateral eye (optic nerve and retina) in physiological conditions. We also observed that, in a rotenone-induced model of retinal damage mimicking LHON, mitochondrial transfer from the healthy to the damaged eye was accelerated and enhanced. Our results thus provide a further explanation for the contralateral beneficial effect observed during clinical studies with lenadogene nolparvovec.
- Published
- 2024
- Full Text
- View/download PDF